Antifungal Evaluation of a Gel Formulation with Nystatin-Loaded Liposomes

This study explores the development of a novel liposomal formulation of Nystatin for transmembrane administration aimed at treating oral mycoses. Traditional Nystatin, though effective, presents systemic toxicity risks. By encapsulating it in cationic liposomes (DPPC/DOTAP/CHOL) and embedding them into alginate hydrogels, the researchers achieved controlled drug release, improved bioavailability, and reduced side effects. The formulations were synthesized via lipid film hydration, characterized by zeta potential, size distribution, and encapsulation efficiency, and evaluated in vitro for antifungal efficacy using Candida albicans ATCC 10231. Results indicated dose-dependent antifungal activity with promising inhibition zones. This liposomal approach offers a safer, targeted alternative to systemic antifungals, particularly beneficial for patients with compromised mucosal barriers or immunosuppression. Future directions include broader microbiological evaluations and optimization of liposomal drug loading.